Cannabis Science Full Report: What a Five-Year Low Back Pain Cannabis Cohort Can and Cannot Tell Us
| Audience | Pain clinicians, primary-care clinicians, patients with chronic low back pain, caregivers, and cannabis-medicine clinicians |
| Primary Topic | How to interpret a five-year inhaled medical-cannabis cohort study in treatment-refractory chronic low back pain |
| Source | Read the full study |
Cannabis Science Full Report: What a Five-Year Low Back Pain Cannabis Cohort Can and Cannot Tell Us
A five-year retrospective analysis of 241 treatment-refractory chronic low back pain patients reported large improvements during inhaled medical-cannabis therapy, alongside major reductions in concomitant pain-medication use. The paper is worth reading because long-term data are rare. It is worth reading skeptically because the design cannot safely establish causality.
| Study Type | Retrospective analysis of prospectively collected single-center outcomes |
| Population | Adults with treatment-refractory chronic low back pain in a tertiary orthopedic clinic |
| Participants | 241 consecutive patients |
| Exposure | Inhaled medical cannabis, predominantly smoked, with THC 4-22% and CBD 2-22% |
| Comparator | Each patient’s documented pre-cannabis baseline during conventional therapy |
| Follow-Up | Five years |
| Pain Signal | Mean NRS change at Year 5 was -5.36 points |
| Function Signal | ODI improved by -17.68 points and BPI interference by -3.41 points |
| Medication Signal | Reported opioid use fell from 100% at baseline to 4.6% at Year 5 |
| Safety Pattern | Recorded adverse events were mostly mild, but follow-up occurred inside a treatment program rather than a randomized safety framework |
| Important Limitation | No concurrent control group, major risk of selection, survivorship, expectancy, and regression-to-the-mean bias |
| Journal | Biomedicines |
| Published | May 30, 2026 |
| PMID | 42351683 |
| DOI | 10.3390/biomedicines14061255 |
The investigators analyzed 241 adults with treatment-refractory chronic low back pain who entered a tertiary orthopedic medical-cannabis program between 2020 and 2025. Outcomes included pain intensity, disability, and pain interference, with follow-up reported out to five years.
By Year 5, the paper reported large average improvements on the Numeric Rating Scale, Oswestry Disability Index, and Brief Pain Inventory, along with marked reductions in concomitant opioid, NSAID, antidepressant, and gabapentinoid use.
Long-term cannabis papers rarely report this much follow-up, and the effect sizes here are much larger than what most short randomized pain trials usually show. That alone makes the paper important to examine carefully.
The authors also describe very high retention and a predominantly mild adverse-event profile. If those patterns reflected a true treatment effect with limited bias, they would represent an unusually strong chronic-pain signal.
This was not a randomized trial, and it did not include a concurrent control group receiving usual care, another analgesic strategy, or placebo. Each patient was effectively compared with their own pre-cannabis history, which leaves major room for regression to the mean, expectation effects, selection into treatment, and survivorship in the program.
The study population came from one center, product exposure was heterogeneous, and the highest-risk claims concern exactly the outcomes that are most vulnerable to bias in open clinical cohorts: pain, disability, and medication behavior over time.
The responsible translation is not that cannabis has now been proven to transform chronic low back pain for most patients. The responsible translation is that some patients in a closely followed real-world program reported substantial long-term improvement while using inhaled cannabis, and that signal deserves comparison against stronger trial designs.
For patients and clinicians, this means the paper can support a careful conversation about goals, monitoring, function, side effects, and alternative explanations. It cannot justify self-directed inhaled-cannabis escalation or broad opioid-replacement claims.
Chronic low back pain is exactly the kind of condition where patients care about long-term function, daily activity, and medication burden, not just short-term pain scores. That makes this paper clinically attractive.
It is also exactly the kind of condition where uncontrolled treatment cohorts can look better than randomized trials because symptom severity, treatment-seeking behavior, and life circumstances fluctuate over time.
The most useful reading keeps both truths in view: long-term observational data matter, and they still require stronger trials before they become clinical proof.
I understand why this paper will get attention. Five-year follow-up in a difficult chronic-pain population is not trivial, and clinicians do need more long-term data than the field usually provides.
What keeps this useful instead of misleading is restraint. I would discuss it as a strong observational signal that raises serious questions worth testing better, not as a settled answer about inhaled cannabis for chronic low back pain.
How to Read a Five-Year Cannabis Low Back Pain Study Without Mistaking It for Proof
Long follow-up can make a paper feel automatically stronger. Sometimes it is. Sometimes it mainly makes the results feel more persuasive than the design can support.
The safest reading starts with admiration for the duration of follow-up and ends with discipline about what an uncontrolled cohort can actually establish.
A Better Reading Order for This Cohort Study
Start with the comparator
Ask what the study compared cannabis against. Here, the comparator was each patient’s earlier conventional-therapy state, not a concurrent randomized control group.
Check retention before celebrating
High retention can be clinically interesting, but it can also reflect who stayed in a treatment program long enough to keep reporting outcomes.
Separate symptom change from causation
Large reductions in pain and disability matter, but in an uncontrolled cohort they do not tell you how much of the change was caused by cannabis itself.
Keep product and route specificity visible
This study involved inhaled medical-cannabis products in one regulatory and clinical setting. It does not validate every dispensary product or every route of administration.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, and critics can read the same data differently. These evidence-based lenses show where this trial is useful, where it remains uncertain, and how easily it can be overstated.
Long-Term Relief Is the Hope, Not the Promise
If you live with chronic low back pain, it makes sense to notice that this cohort reported improvement in pain, disability, and medication use over several years.
It also matters that this was not a randomized proof study. The paper supports a conversation about possibilities and tradeoffs, not a guarantee that inhaled cannabis will help you the same way.
Useful Counseling Data With a High Bias Burden
Clinicians can use this paper to discuss what some patients report over long follow-up in a regulated cannabis program, especially around function and medication trajectories.
But the counseling value depends on naming the biases clearly. Without that, the paper can be mistaken for proof of efficacy and proof of opioid sparing.
The Design Can Magnify Benefit
A skeptical read should focus first on the lack of concurrent control, the within-patient historical comparison, and the unusually favorable long-term retention profile.
Those features do not erase the reported improvements, but they do make it impossible to assign the observed gains confidently to cannabis alone.
Function and Medication Burden Matter
Pain care is not only about a numeric pain score. Disability, activity interference, and the broader treatment burden are also meaningful outcomes for patients with long-standing low back pain.
This paper is valuable partly because it keeps those outcomes visible. It is incomplete because it cannot show whether a different pain strategy might have produced similar changes.
Mild Adverse Events Do Not End the Safety Conversation
The paper describes mostly mild adverse events, which is reassuring at first glance. But safety in an open treatment program is not the same thing as safety adjudication in a blinded controlled trial.
Sedation, impairment, falls risk, cognitive effects, and inhalation-related concerns still need patient-specific review, especially over long-term use.
Observational and Randomized Evidence Answer Different Questions
This cohort tells us what a long-running clinical program observed. Randomized pain trials tell us more about average causal effects under controlled conditions.
When the cohort looks much stronger than the trial literature, the right move is synthesis and skepticism, not choosing whichever evidence layer feels more hopeful.
Monitor Goals, Function, and Impairment Together
If medical cannabis is considered, follow-up should track pain, mobility, work tolerance, sleep, medication changes, impairment, and adverse effects in a structured way.
That practical monitoring frame is more defensible than assuming long-term benefit because one observational paper reported dramatic averages.
The Next Step Is Better Comparative Pain Trials
What this study most clearly earns is a better-designed next study: clearer product definitions, concurrent controls, stronger safety capture, and longer comparative follow-up.
The field does not need more generic cannabis-pain rhetoric. It needs low back pain trials that can separate durable benefit from durable bias.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved.
CED coverage of a randomized Veterans trial protocol for oral dronabinol in chronic low back pain.
CED coverage of a regulated full-spectrum extract positioned around phase 3 low-back-pain evidence and FDA breakthrough status.
CED coverage of observational state-program data linking medical cannabis with pain-related functional improvement.
Frequently Asked Questions
What type of study was this?
It was a retrospective analysis of prospectively collected outcomes from a single-center medical-cannabis cohort, not a randomized controlled trial.
Who was studied?
The paper analyzed 241 adults with treatment-refractory chronic low back pain treated in a tertiary orthopedic clinic.
What kind of cannabis therapy did patients receive?
Patients used inhaled medical-cannabis products, predominantly smoked, with THC concentrations ranging from 4% to 22% and CBD concentrations ranging from 2% to 22%.
What outcomes improved in the paper?
The paper reported large average improvements in pain intensity, disability, pain interference, and reductions in use of several concomitant pain-related medications by Year 5.
Does this prove cannabis caused those improvements?
No. Without a concurrent control group, the study cannot confidently separate a cannabis effect from selection bias, expectancy, regression to the mean, retention effects, or other treatment changes over time.
Why is the lack of a control group such a big issue?
Because chronic pain symptoms and treatment behavior can change for many reasons over time. A concurrent control helps show whether similar patients improved without the same cannabis exposure.
Does this prove an opioid-sparing effect?
No. The reported reduction in opioid use is clinically interesting, but in an uncontrolled cohort it cannot be treated as proof that cannabis itself caused the change.
How should clinicians use this paper?
Clinicians can use it to inform careful counseling about long-term observational signals, while making the design limits explicit and keeping monitoring goals concrete.
Should patients take this as a reason to start smoking cannabis for back pain?
No. The paper does not validate self-directed smoking, specific retail products, or unsupervised long-term use for chronic low back pain.
What is the safest bottom-line interpretation?
The study reports a meaningful long-term chronic-pain signal in a real-world medical-cannabis cohort, but the evidence remains observational and cannot justify broad causal or prescribing claims on its own.
